CADL
Candel Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +30.0% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 64 | +11 | 29.28M | $301.40M | +14 | −3 |
| Q1 2026 | 56 | +7 | 21.92M | $107.44M | +12 | −5 |
| Q4 2025 | 49 | -3 | 17.41M | $98.31M | — | −3 |
| Q3 2025 | 14 | 0 | 15.17M | $77.37M | +2 | −2 |
| Q2 2025 | 11 | +1 | 14.70M | $74.37M | +3 | −2 |
| Q1 2025 | 7 | +2 | 1.74M | $9.82M | +2 | — |
| Q4 2024 | 5 | 0 | 1.36M | $11.81M | — | — |
| Q3 2024 | 4 | +1 | 482.85K | $3.35M | +2 | −1 |
| Q2 2024 | 3 | — | 435.83K | $2.70M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 560.97K | — | $4.87M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 455.42K | +1.4% | $3.95M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 455.42K | +1.4% | $3.95M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 291.15K | +288166.3% | $2.53M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Millennium Management ✦ | 31.63K | +130.6% | $274,514 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 21.86K | +9.1% | $189,736 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 21.86K | +9.1% | $189,736 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 113 holders, 43.40M shares, $212.35M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 7.00K sh · $84,000
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology